Recruiting
Phase 1

CUG279

Sponsor:

Cugene Inc.

Code:

NCT07946302

Conditions

Advanced Solid Tumor (Phase 1)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CUG279

Study Details

Brief summary:

CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.

Conditions

Advanced Solid Tumor (Phase 1)

Study ID

NCT07946302

Start date

Nov 5, 2026

Status verified date

Nov, 2026

Completion date

Mar 30, 2029

Anticipated

Primary completion date

Mar 30, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Signed and dated informed consent.
2. Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
3. At least 1 measurable lesion according to RECIST v1.1.
4. Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
6. Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
7. Life expectancy of ≥3 months.
8. Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.

Exclusion Criteria

1. Rapidly progressing disease or disease requiring urgent alternative medical intervention.
2. Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
3. Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
4. Concurrent participation in another interventional therapeutic clinical trial.
5. Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
6. Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
7. Unresolved clinically significant toxicities from prior anticancer therapy.
8. Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
9. Active or clinically significant infection except as specified in the protocol.
10. Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
11. Known hypersensitivity or significant allergic reaction to biologics or its components.
12. Recent vaccination, except as permitted by the protocol.
13. Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results

Study Design

Enrollment

65 participants

Anticipated

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Part A Dose Escalation

CUG279 will be administered at multiple ascending dose levels

Interventions

CUG279

CUG279 will be administered intravenously according to the protocol

Primary outcome measure

  • Incidence of dose limiting toxicities (DLTs) [ Time Frame: From the first dose up to 21 days post-dose ]
  • Incidence and severity of treatment-emergent adverse events (TEAEs) [ Time Frame: From first dose through 90 days after the last dose ]
  • Incidence of serious adverse events (SAEs) [ Time Frame: From first dose through 90 days after the last dose ]
  • Clinically significant changes in safety laboratory parameters from baseline [ Time Frame: From first dose through 90 days after the last dose ]
  • Clinically significant changes in electrocardiogram (ECG) findings from baseline [ Time Frame: From first dose through 90 days after the last dose ]
  • Clinically significant changes in vital signs from baseline [ Time Frame: From first dose through 90 days after the last dose ]
  • Incidence of TEAEs leading to dose modifications [ Time Frame: From the first dose through the last dose; up to 1 year ]

Central Contacts and Locations

Central contacts

Locations

NEXT Virginia

Recruiting

Fairfax, Virginia, United States, 22031

More Information

Sponsor

Cugene Inc.

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • advanced solid tumor
  • metastic solid tumors
  • phase 1
  • first in human
  • CUG279
  • dose escalation
  • dose expansion
  • immunotherapy
  • immuno-oncology
  • IL-2
  • Interleuken-2

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Cugene Inc. on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.